Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT04186403. We help you review the study, but cannot decide medical eligibility.
CompletedNCT04186403
Brexpiprazole for Borderline Personality Disorder
This study is completed in the United States. It is testing brexpiprazole for Borderline Personality Disorder.
Personality disorders, Borderline personalityDrugFrom 18 Years to 65 Years
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- New York, United StatesSee all locations and recruitment
Compensation and expense reimbursement have not been verified for this summary.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 13, 2020
- Recruitment status
- Completed
- Enrollment listed in the registry
- 201
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04186403
- Official title
- A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adult Subjects With Borderline Personality Disorder
Recruitment & locations
CompletedNew York
Registry details
Registry conditions (original wording)
Borderline Personality Disorder; Borderline Personality Disorder Trastorno límite de la personalidad
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including Brexpiprazole.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as completed.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT02507206
A D1 Agonist For Working Memory
This study is completed. It focuses on personality disorders and currently lists study information in the United States.
CompletedNCT04566601
A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder
This study is completed in the United States, in Australia, in France, .... It focuses on Personality disorders.
CompletedNCT04100096
A study of Brexpiprazole in the Treatment of Borderline Personality Disorder
This study is completed. It focuses on personality disorders and currently lists study information in Spain, Ukraine, and the United States.